{"id":"W2906220152","doi":"10.1182/blood-2018-99-117824","title":"MCRN¯003/MYX·1: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma after 1-3 Prior Therapies","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; London Health Sciences Centre; Western University; Saint John Regional Hospital; Hôtel-Dieu de Québec; University of Ottawa; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Alberta; University of New Brunswick; Université de Montréal; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Carfilzomib; Medicine; Dexamethasone; Cyclophosphamide; Internal medicine; Multiple myeloma; Oncology; Refractory (planetary science); Phases of clinical research; Progressive disease; Lenalidomide; Clinical trial; Gastroenterology; Pharmacology; Urology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001681898,0.001328044,0.001983212,0.000477687,0.0005147893,0.001045871,0.001308454,0.00134848,0.003781838],"category_scores_gemma":[0.000576523,0.0006479146,0.001126028,0.0003071123,0.0008123724,0.0007198536,0.0003348288,0.003654146,0.000797822],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008674874,"about_ca_system_score_gemma":0.001590779,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001395434,"about_ca_topic_score_gemma":0.003406403,"domain_scores_codex":[0.9995824,0.0001570859,0.00001992738,0.00008170264,0.00004921516,0.0001097097],"domain_scores_gemma":[0.9994262,0.00006601513,0.00008940251,0.00003694066,0.00003012756,0.0003513336],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6613693,0.1851763,0.002768934,0.0008496899,0.001057206,0.0002721794,0.0002548456,0.001891461,0.06262606,0.0002338964,0.00251893,0.0809812],"study_design_scores_gemma":[0.4131123,0.5776912,0.004356034,0.0000203208,0.0002279737,0.0001241467,0.00002601187,0.0006679904,0.00272333,0.0000659581,0.0009655035,0.00001910714],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942458,0.001216342,0.000357219,0.0002698179,0.0001313292,0.002262582,0.0003504863,0.00009732445,0.001069136],"genre_scores_gemma":[0.989979,0.001222536,0.001424965,0.0004784051,0.000212738,0.002296345,0.0008240384,0.00001996457,0.003541925],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003781838,"threshold_uncertainty_score":0.01265144,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02892129428876425,"score_gpt":0.3029793129505857,"score_spread":0.2740580186618214,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}